Cargando…

Mortality and use of psychotropic medication in patients with stroke: a population-wide, register-based study

OBJECTIVES: The study sought to describe whether psychotropic medication may have long-term side effects in patients with stroke compared with controls. SETTING: Use of national register data from healthcare services were identified from the Danish National Patient Registry in Denmark. Information a...

Descripción completa

Detalles Bibliográficos
Autores principales: Jennum, Poul, Baandrup, Lone, Iversen, Helle K, Ibsen, Rikke, Kjellberg, Jakob
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4785303/
https://www.ncbi.nlm.nih.gov/pubmed/26956165
http://dx.doi.org/10.1136/bmjopen-2015-010662
_version_ 1782420383955156992
author Jennum, Poul
Baandrup, Lone
Iversen, Helle K
Ibsen, Rikke
Kjellberg, Jakob
author_facet Jennum, Poul
Baandrup, Lone
Iversen, Helle K
Ibsen, Rikke
Kjellberg, Jakob
author_sort Jennum, Poul
collection PubMed
description OBJECTIVES: The study sought to describe whether psychotropic medication may have long-term side effects in patients with stroke compared with controls. SETTING: Use of national register data from healthcare services were identified from the Danish National Patient Registry in Denmark. Information about psychotropic medication use was obtained from the Danish Register of Medicinal Product Statistics. OBJECTIVES: We aimed to evaluate all-cause mortality in relation to the use of benzodiazepines, antidepressants and antipsychotics in patients with stroke and matched controls. PARTICIPANTS: Patients with a diagnosis of stroke and either no drug use or preindex use of psychotropic medication (n=49 968) and compared with control subjects (n=86 100) matched on age, gender, marital status and community location. PRIMARY OUTCOME MEASURE: All-cause mortality. RESULTS: All-cause mortality was higher in patients with previous stroke compared with control subjects. Mortality HRs were increased for participants prescribed serotonergic antidepressant drugs (HR=1.699 (SD=0.030), p=0.001 in patients; HR=1.908 (0.022), p<0.001 in controls, respectively), tricyclic antidepressants (HR=1.365 (0.045), p<0.001; HR=1.733 (0.022), p<0.001), benzodiazepines (HR=1.643 (0.040), p<0.001; HR=1.776 (0.053), p<0.001), benzodiazepine-like drugs (HR=1.776 (0.021), p<0.001; HR=1.547 (0.025), p<0.001), first-generation antipsychotics (HR=2.001 (0.076), p<0.001; HR=3.361 (0.159), p<0.001) and second-generation antipsychotics (HR=1.645 (0.070), p<0.001; HR=2.555 (0.086), p<0.001), compared with no drug use. Interaction analysis suggested statistically significantly higher mortality HRs for most classes of psychotropic drugs in controls compared with patients with stroke. CONCLUSIONS: All-cause mortality was higher in patients with stroke and controls treated with benzodiazepines, antidepressants and antipsychotics than in their untreated counterparts. Our findings suggest that care should be taken in the use and prescription of such drugs, and that they should be used in conjunction with adequate clinical controls.
format Online
Article
Text
id pubmed-4785303
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-47853032016-03-14 Mortality and use of psychotropic medication in patients with stroke: a population-wide, register-based study Jennum, Poul Baandrup, Lone Iversen, Helle K Ibsen, Rikke Kjellberg, Jakob BMJ Open Neurology OBJECTIVES: The study sought to describe whether psychotropic medication may have long-term side effects in patients with stroke compared with controls. SETTING: Use of national register data from healthcare services were identified from the Danish National Patient Registry in Denmark. Information about psychotropic medication use was obtained from the Danish Register of Medicinal Product Statistics. OBJECTIVES: We aimed to evaluate all-cause mortality in relation to the use of benzodiazepines, antidepressants and antipsychotics in patients with stroke and matched controls. PARTICIPANTS: Patients with a diagnosis of stroke and either no drug use or preindex use of psychotropic medication (n=49 968) and compared with control subjects (n=86 100) matched on age, gender, marital status and community location. PRIMARY OUTCOME MEASURE: All-cause mortality. RESULTS: All-cause mortality was higher in patients with previous stroke compared with control subjects. Mortality HRs were increased for participants prescribed serotonergic antidepressant drugs (HR=1.699 (SD=0.030), p=0.001 in patients; HR=1.908 (0.022), p<0.001 in controls, respectively), tricyclic antidepressants (HR=1.365 (0.045), p<0.001; HR=1.733 (0.022), p<0.001), benzodiazepines (HR=1.643 (0.040), p<0.001; HR=1.776 (0.053), p<0.001), benzodiazepine-like drugs (HR=1.776 (0.021), p<0.001; HR=1.547 (0.025), p<0.001), first-generation antipsychotics (HR=2.001 (0.076), p<0.001; HR=3.361 (0.159), p<0.001) and second-generation antipsychotics (HR=1.645 (0.070), p<0.001; HR=2.555 (0.086), p<0.001), compared with no drug use. Interaction analysis suggested statistically significantly higher mortality HRs for most classes of psychotropic drugs in controls compared with patients with stroke. CONCLUSIONS: All-cause mortality was higher in patients with stroke and controls treated with benzodiazepines, antidepressants and antipsychotics than in their untreated counterparts. Our findings suggest that care should be taken in the use and prescription of such drugs, and that they should be used in conjunction with adequate clinical controls. BMJ Publishing Group 2016-03-08 /pmc/articles/PMC4785303/ /pubmed/26956165 http://dx.doi.org/10.1136/bmjopen-2015-010662 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Neurology
Jennum, Poul
Baandrup, Lone
Iversen, Helle K
Ibsen, Rikke
Kjellberg, Jakob
Mortality and use of psychotropic medication in patients with stroke: a population-wide, register-based study
title Mortality and use of psychotropic medication in patients with stroke: a population-wide, register-based study
title_full Mortality and use of psychotropic medication in patients with stroke: a population-wide, register-based study
title_fullStr Mortality and use of psychotropic medication in patients with stroke: a population-wide, register-based study
title_full_unstemmed Mortality and use of psychotropic medication in patients with stroke: a population-wide, register-based study
title_short Mortality and use of psychotropic medication in patients with stroke: a population-wide, register-based study
title_sort mortality and use of psychotropic medication in patients with stroke: a population-wide, register-based study
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4785303/
https://www.ncbi.nlm.nih.gov/pubmed/26956165
http://dx.doi.org/10.1136/bmjopen-2015-010662
work_keys_str_mv AT jennumpoul mortalityanduseofpsychotropicmedicationinpatientswithstrokeapopulationwideregisterbasedstudy
AT baandruplone mortalityanduseofpsychotropicmedicationinpatientswithstrokeapopulationwideregisterbasedstudy
AT iversenhellek mortalityanduseofpsychotropicmedicationinpatientswithstrokeapopulationwideregisterbasedstudy
AT ibsenrikke mortalityanduseofpsychotropicmedicationinpatientswithstrokeapopulationwideregisterbasedstudy
AT kjellbergjakob mortalityanduseofpsychotropicmedicationinpatientswithstrokeapopulationwideregisterbasedstudy